We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

73 hedge funds and large institutions have $905M invested in Kinnate Biopharma Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 32 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

256% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 9

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

18% more funds holding

Funds holding: 62 → 73 (+11)

2% more capital invested

Capital invested by funds: $891M → $905M (+$14.4M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
73
Holders Change
+11
Holders Change %
+17.74%
% of All Funds
1.28%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
17
Increased
32
Reduced
9
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$17M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$14.6M
3
BlackRock
BlackRock
New York
+$13.1M
4
Morgan Stanley
Morgan Stanley
New York
+$6.88M
5
NHAS
Novo Holdings A/S
Denmark
+$4.32M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$26.9M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$10.4M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$10.4M
4
Franklin Resources
Franklin Resources
California
-$4.47M
5
Citadel Advisors
Citadel Advisors
Florida
-$3.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$309K +$115K +5,271 +65%
DCM
52
Dupont Capital Management
Delaware
$283K +$268K +12,315 New
New York State Common Retirement Fund
53
New York State Common Retirement Fund
New York
$243K -$56K -2,573 -20%
MIM
54
MetLife Investment Management
New Jersey
$229K +$216K +9,927 New
VOYA Investment Management
55
VOYA Investment Management
Georgia
$212K +$200K +9,198 New
Two Sigma Investments
56
Two Sigma Investments
New York
$206K +$194K +8,928 New
Invesco
57
Invesco
Georgia
$205K +$194K +8,906 New
MLICM
58
Metropolitan Life Insurance Company (MetLife)
New York
$173K +$163K +7,510 New
CSS
59
Cubist Systematic Strategies
Connecticut
$169K +$160K +7,361 New
Legal & General Group
60
Legal & General Group
United Kingdom
$97K +$67.5K +3,102 +276%
Citigroup
61
Citigroup
New York
$87K +$52.1K +2,395 +171%
Royal Bank of Canada
62
Royal Bank of Canada
Ontario, Canada
$85K +$35.9K +1,651 +82%
SO
63
STRS Ohio
Ohio
$75K – – –
AIP
64
Ameritas Investment Partners
Nebraska
$45K +$19K +874 +80%
PHK
65
Point72 Hong Kong
Hong Kong
$43K +$40.5K +1,862 New
UBS Group
66
UBS Group
Switzerland
$17K +$10.4K +478 +190%
TRCT
67
Tower Research Capital (TRC)
New York
$12K -$2.52K -116 -18%
S
68
SignatureFD
Georgia
$5K +$3.48K +160 +271%
PA
69
Parallel Advisors
California
$5K +$4.33K +199 New
US Bancorp
70
US Bancorp
Minnesota
$2K +$1.09K +50 +100%
Wells Fargo
71
Wells Fargo
California
$1K -$2.02K -93 -67%
QCG
72
Quadrant Capital Group
Ohio
$1K +$479 +22 New
T. Rowe Price Associates
73
T. Rowe Price Associates
Maryland
– -$10.4M -445,477 Closed
Franklin Resources
74
Franklin Resources
California
– -$4.47M -192,100 Closed
TD Asset Management
75
TD Asset Management
Ontario, Canada
– -$807K -37,407 Closed
1 2
3
4

KNTE Hedge Fund Activity: Q3 2021 in Review

73 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q3 2021, worth a combined $905M — up 1.6% from $891M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KNTE positions and 6 closed out — a net gain of 11 holders — while 32 added to existing stakes and 9 trimmed.

The largest buyer was Boxer Capital, adding an estimated $17M. The largest seller was Logos Global Management, cutting an estimated $26.9M.

  • 73 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q3 2021, up from 62 in Q2 2021.
  • Funds reported $905M of Kinnate Biopharma Inc. Common Stock stock for Q3 2021, up 1.6% quarter-over-quarter.
  • 17 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q3 2021 and 6 closed out, a net change of +11 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q3 2021 was Boxer Capital, an estimated $17M added.
  • The largest Kinnate Biopharma Inc. Common Stock seller in Q3 2021 was Logos Global Management, an estimated $26.9M sold.

Based on aggregated 13F filings for Q3 2021.